TARS (Tarsus Pharmaceuticals) Change In Receivables: $-53.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $59.85
GF Value $206.79
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Change In Receivables?

Tarsus Pharmaceuticals TARS +3.58% 47 Change In Receivables is $-53.1 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $206.79 (Possible Value Trap). The stock has 2 warning signs investors should review.

Tarsus Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was $-30.1 Mil. It means Tarsus Pharmaceuticals's Accounts Receivable increased by $30.1 Mil from Dec. 2025 to Mar. 2026 .

Tarsus Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $-39.1 Mil. It means Tarsus Pharmaceuticals's Accounts Receivable increased by $39.1 Mil from Dec. 2024 to Dec. 2025 .

Tarsus Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was $100.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Tarsus Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2026 was 56.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tarsus Pharmaceuticals's liquidation value for the three months ended in Mar. 2026 was $234.1 Mil.

Tarsus Pharmaceuticals  (NAS:TARS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Tarsus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=100.344/162.054*91
=56.50

2. In Ben Graham's calculation of liquidation value, Tarsus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Tarsus Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=388.732-232.184+0.75 * 100.344+0.5 * 4.572
=234.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Change In Receivables Related Terms

Tarsus Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Change In Receivables Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -0.07 -3.49 -14.13 -30.35 -39.05

Tarsus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.10 3.91 -14.10 -12.77 -30.10
TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-53.1 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Change In Receivables of $-53.1 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Change In Receivables too high?
Tarsus Pharmaceuticals' current Change In Receivables is $-53.1 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Change In Receivables compare to KLRA and CLDX?
Tarsus Pharmaceuticals' Change In Receivables of $-53.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Change In Receivables is $-53.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $206.79, compared to a current price of $59.85 — trading 71.1% below its estimated fair value. The current Change In Receivables is $-53.1 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Change In Receivables is $-53.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $59.85 is trading 71.1% below its estimated GF Value™ of $206.79. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Change In Receivables: $-53.1 Mil
  • GF Value™: $206.79 vs. price of $59.85 (71.1% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.85
Price
$206.79
GF Value